The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Albert GrinshpunSara M TolaneyHarold J BursteinRinath M JeselsohnErica L MayerPublished in: NPJ breast cancer (2023)
Keyphrases